Biomark Diagnostics Inc. (CSE:BUX)

Market Cap	33.22M
Revenue (ttm)	154.90K
Net Income (ttm)	-1.72M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,000
Average Volume	20,854
Open	0.3450
Previous Close	0.3500
Day's Range	0.3200 - 0.3500
52-Week Range	0.1800 - 0.3750
Beta	-0.32
RSI	44.77
Earnings Date	Nov 27, 2025

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BUX

Financial Performance

In 2024, Biomark Diagnostics's revenue was 154,216, a decrease of -5.52% compared to the previous year's 163,220. Losses were -1.93 million, 35.0% more than in 2023.